{
    "Trade/Device Name(s)": [
        "Clearblue\u00ae Early Pregnancy Test"
    ],
    "Submitter Information": "SPD Swiss Precision Diagnostics GmbH",
    "510(k) Number": "K213379",
    "Predicate Device Reference 510(k) Number(s)": [
        "K123436"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCX"
    ],
    "Summary Letter Date": "June 24, 2022",
    "Summary Letter Received Date": "July 5, 2022",
    "Submission Date": "June 24, 2022",
    "Regulation Number(s)": [
        "21CFR862.1155"
    ],
    "Regulation Name(s)": [
        "Human Chorionic Gonadotropin (hCG) Test System"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Human Chorionic Gonadotropin (hCG)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic sandwich assay",
        "Lateral flow assay",
        "Visual detection"
    ],
    "Methodologies": [
        "Immunoassay",
        "Lateral flow",
        "Sandwich assay"
    ],
    "Submission Type(s)": [
        "Kit",
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for Clearblue\u00ae Early Pregnancy Test, an OTC visual chromatographic immunoassay for qualitative detection of hCG in urine to aid in early pregnancy detection",
    "Indications for Use Summary": "Over-the-counter chromatographic immunoassay for qualitative detection of human chorionic gonadotropin (hCG) in urine as an aid in early pregnancy detection, for home use as early as six days before missed period",
    "fda_folder": "Clinical Chemistry"
}